

IVD Raw Materials Market - Global Outlook & Forecast 2022-2027

Market Report | 2022-06-20 | 342 pages | Arizton Advisory & Intelligence

AVAILABLE LICENSES:

- Single User License \$3500.00
- Team License \$3995.00
- Enterprisewide \$4995.00

Report description:

The IVD raw materials market by revenue is expected to grow at a CAGR of 5.86% during 2022-2027.

The following factors are likely to contribute to the growth of the IVD raw materials market during the forecast period:

- Increasing Prevalence of Infectious & Chronic Diseases
- Growing Awareness for Early Diagnosis and Disease Prevention
- -□Surge In Demand for IVD Testing & Devices
- Rise In Availability of Advanced Home Care Kits for Cancer Diagnostics

With the rise in chronic conditions and patient populations, the demand for diagnostics and laboratory tests increases. The growing demand for antigen and antibody-based tests that increased during COVID-19 led to its major market share.

The Europe region is one of the matured markets for in-vitro diagnostic; the large laboratory instruments are highly automated compared to most point-of-care testing devices. Automation has increased the speed and ease of using the devices the workforce is thoroughly trained and adopted. Furthermore, the global IVD raw materials market is expected to witness an incremental growth of USD 9.91 billion and absolute growth of 40.73% by 2027.

KEY HIGHLIGHTS

- Growing trends for point of care diagnostics and personalized medicine contribute to the growth of the IVD raw materials market.
- Investment in the development and commercial launch of IVD instruments and rapid test kits to diagnose several infectious diseases and their applications in the research segment will boost the market in developed countries.
- In 2021, pharma & biotech companies accounted for the major share of 62.19% in the global IVD raw materials market. However, diagnostic laboratories are likely to witness the highest absolute growth of 43.37% during the forecast period.
- -[Vendors offer a broad portfolio of quality enzymes that are highly suitable for manufacturing diagnostic kits and reagents.

Manufacturers are also exploring new enzyme sources from enormous enzymes and optimizing and transforming the most appropriate enzyme molecules.

THIS RESEARCH REPORT INCLUDE A DETAILED SEGMENTATION ANALYSIS BY:

- -□Product
- -[]Technology
- -□End-User
- Geography

SEGMENTATION ANALYSIS

Rapid tests developed through clinical chemistry provides test results immediately. Manufacturers offer many IVD raw materials applicable to clinical chemistry methods. The global IVD raw materials market by clinical chemistry is expected to reach USD 12.14 billion by 2027. Furthermore, private laboratories have expanded their footprints in recent years, especially in developing countries, which has stimulated market growth. Moreover, the demand for standalone reference laboratories is gradually rising due to the prevalence of epidemic and pandemic conditions across the global IVD raw materials market by diagnostic laboratories will grow at a CAGR of over 6% during 2022-2027.

- Segmentation Analysis by Product
- o

 ☐Antibody & Antigen
- o

 Enzymes
- o∏Proteins
- o

 Biological Buffers
- o∏Others
- -□Segmentation Analysis by Technology
- o
 ☐Clinical Chemistry
- o[Immunochemistry
- o∏Molecular Diagnostics
- o∏Others
- -∏Segmentation Analysis by End-User
- o∏Pharma & Biotech Companies
- o

 Diagnostic Laboratories
- o∏Others

COMPETITIVE LANDSCAPE

Major manufacturers of IVD raw materials are focusing on their proprietary processing techniques that satisfy the raw material requirements of the IVD industry and provide IVD raw materials made to their own with the off-the-shelf specification. Vendors are constantly investing resources in R&D projects based on market trends and the demand for general health management. Key players are also engaged in strategic acquisitions as part of their inorganic growth strategy to enhance sales and profit margins. Strategic M&As continue to be an essential competitive strategy for key players to expand product offerings, access new technology, or increase market share. Vendors also focus on developing and commercializing innovative analyzers, COVID-19 PCR rapid test kits, and consumables to remain competitive and gain a significant presence in the IVD raw materials market.

Key Vendors

Scotts International, EU Vat number: PL 6772247784

- Aalto Bio Reagents
- -□Fapon Biotech
- Fujirebio
- Merck KGaA
- -□Hoffmann-La Roche
- Thermo Fisher Scientific

Other Prominent Vendors

- -∏ABclonal
- -∏BBI Solutions
- -∏Beijing Diagreat Biotechnology
- -□Biofootprints Healthcare
- -∏BioPorto
- —Creative Diagnostics
- CUSABIO Technology
- EUPROTEIN
- -□Eximio Biotec
- -□GenScript ProBio
- -□Getein Biotech
- -∏Glentham Life Sciences
- -[]HyTest
- Immuno Diagnostics
- -∏LGC
- Medix Biochemica
- -□Meridian Bioscience
- More Diagnostics
- -□MP Biomedicals
- Nanjing Okay Biotechnology
- -□Nitto Boseki
- -∏OYC Europe
- -□Prahas Healthcare
- -□Promega
- -∏ReAgent
- Rockland Immunochemicals
- Sekisui Diagnostics
- -□SERION Immunologics
- -□Signalway Antibody
- -□Suzhou Yacoo Science
- -□Trina Bioreactives
- -∏Watson International
- -□Wuhan Huamei Biotech

GEOGRAPHICAL ANALYSIS

In 2021, Europe dominated the global IVD raw materials market compared to other regions. This region is a mature market with developed diagnostic infrastructure available in most countries. The demand for advanced molecular diagnostics in the European countries has gone high owing to the presence of advanced infrastructure in healthcare diagnosis. Point of care diagnostics is the latest trend in the European market. The Europe IVD raw materials market is expected to reach USD 11.80 billion by 2027.

Scotts International, EU Vat number: PL 6772247784

-[Geography

- o[Europe
- -□Germany
- -□Italy
- -□France
- -∏UK
- -□Spain
- o∏North America
- -[]US
- -[Canada
- o∏APAC
- -□China
- -∐apan
- -□India
- -□Australia
- -□South Korea
- o∏Latin America
- -□Brazil
- -□Mexico
- $\hbox{-} \square Argentina$
- o∏Middle East & Africa
- -[]Turkey
- -□Saudi Arabia
- -∏South Africa

Table of Contents:

- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS
- 4 SCOPE & COVERAGE
- 4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
- 4.2 BASE YEAR
- 4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY PRODUCT
- 4.3.2 MARKET SEGMENTATION BY TECHNOLOGY
- 4.3.3 MARKET SEGMENTATION BY END USER
- 4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
- **5 REPORT ASSUMPTIONS & CAVEATS**
- **5.1 KEY CAVEATS**
- 5.2 CURRENCY CONVERSION

Scotts International. EU Vat number: PL 6772247784

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 OVERVIEW

8 MARKET OPPORTUNITIES & TRENDS

- 8.1 GROWING DEMAND FOR POINT-OF-CARE PCR DIAGNOSTICS
- 8.2 SURGE IN PREFERENCE FOR PERSONALIZED MEDICINE
- 8.3 RISE IN DEMAND FOR MOLECULAR DIAGNOSTICS
- 8.4 ADVANCED TECHNOLOGIES IN IVD PRODUCTS

9 MARKET GROWTH ENABLERS

- 9.1 INCREASING PREVALENCE OF INFECTIOUS & CHRONIC DISEASES
- 9.2 GROWING AWARENESS OF EARLY DIAGNOSIS AND DISEASE PREVENTION
- 9.3 HIGH DEMAND FOR IVD TESTS & DEVICES
- 9.4 RISE IN AVAILABILITY OF ADVANCED HOME CARE KITS FOR CANCER DIAGNOSTICS

10 MARKET RESTRAINTS

- 10.1 LOT-TO-LOT VARIATIONS IN IVD REAGENTS
- 10.2 STRINGENT REGULATIONS FOR PRODUCT APPROVALS
- 10.3 LOWER PENETRATION OF IVD DEVICES IN LMICS

11 MARKET LANDSCAPE

- 11.1 MARKET OVERVIEW
- 11.2 MARKET SIZE & FORECAST
- 11.2.1 DEMAND FOR IVD RAW MATERIALS DURING COVID-19
- 11.3 FIVE FORCES ANALYSIS
- 11.3.1 THREAT OF NEW ENTRANTS
- 11.3.2 BARGAINING POWER OF SUPPLIERS
- 11.3.3 BARGAINING POWER OF BUYERS
- 11.3.4 THREAT OF SUBSTITUTES
- 11.3.5 COMPETITIVE RIVALRY

12 PRODUCT

- 12.1 MARKET SNAPSHOT & GROWTH ENGINE
- 12.2 MARKET OVERVIEW
- 12.3 ANTIBODIES & ANTIGENS
- 12.3.1 MARKET OVERVIEW
- 12.3.2 MARKET SIZE & FORECAST
- 12.3.3 ANTIBODIES & ANTIGENS: GEOGRAPHY SEGMENTATION
- 12.4 ENZYMES
- 12.4.1 MARKET OVERVIEW
- 12.4.2 MARKET SIZE & FORECAST
- 12.4.3 ENZYMES: GEOGRAPHY SEGMENTATION
- 12.5 PROTEINS
- 12.5.1 MARKET OVERVIEW

Scotts International. EU Vat number: PL 6772247784

- 12.5.2 MARKET SIZE & FORECAST
- 12.5.3 PROTEINS: GEOGRAPHY SEGMENTATION
- 12.6 BIOLOGICAL BUFFERS
- 12.6.1 MARKET OVERVIEW
- 12.6.2 MARKET SIZE & FORECAST
- 12.6.3 BIOLOGICAL BUFFERS: GEOGRAPHY SEGMENTATION
- **12.7 OTHERS**
- 12.7.1 MARKET OVERVIEW
- 12.7.2 MARKET SIZE & FORECAST
- 12.7.3 OTHERS: GEOGRAPHY SEGMENTATION
- 13 TECHNOLOGY
- 13.1 MARKET SNAPSHOT & GROWTH ENGINE
- 13.2 MARKET OVERVIEW
- 13.3 CLINICAL CHEMISTRY
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 CLINICAL CHEMISTRY: GEOGRAPHY SEGMENTATION
- 13.4 IMMUNOCHEMISTRY
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 IMMUNOCHEMISTRY: GEOGRAPHY SEGMENTATION
- 13.5 MOLECULAR DIAGNOSTICS
- 13.5.1 MARKET OVERVIEW
- 13.5.2 MARKET SIZE & FORECAST
- 13.5.3 MOLECULAR DIAGNOSTICS: GEOGRAPHY SEGMENTATION
- **13.6 OTHERS**
- 13.6.1 MARKET OVERVIEW
- 13.6.2 MARKET SIZE & FORECAST
- 13.6.3 OTHERS: GEOGRAPHY SEGMENTATION
- 14 END USER
- 14.1 MARKET SNAPSHOT & GROWTH ENGINE
- 14.2 MARKET OVERVIEW
- 14.3 PHARMA/BIOTECH & MEDTECH COMPANIES
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 PHARMA/BIOTECH & MEDTECH COMPANIES: GEOGRAPHY SEGMENTATION
- 14.4 DIAGNOSTIC LABORATORIES
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 DIAGNOSTIC LABORATORIES: GEOGRAPHY SEGMENTATION
- 14.5 OTHERS
- 14.5.1 MARKET OVERVIEW
- 14.5.2 MARKET SIZE & FORECAST
- 14.5.3 OTHERS: GEOGRAPHY SEGMENTATION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15 GEOGRAPHY

- 15.1 MARKET SNAPSHOT & GROWTH ENGINE
- 15.2 GEOGRAPHIC OVERVIEW

16 EUROPE

- 16.1 MARKET OVERVIEW
- 16.2 MARKET SIZE & FORECAST
- 16.2.1 EUROPE: PRODUCT
- 16.2.2 EUROPE: TECHNOLOGY
- 16.2.3 EUROPE: END USER
- 16.3 KEY COUNTRIES
- 16.3.1 GERMANY: MARKET SIZE & FORECAST
- 16.3.2 ITALY: MARKET SIZE & FORECAST
- 16.3.3 FRANCE: MARKET SIZE & FORECAST
- 16.3.4 UK: MARKET SIZE & FORECAST
- 16.3.5 SPAIN: MARKET SIZE & FORECAST

17 NORTH AMERICA

- 17.1 MARKET OVERVIEW
- 17.2 MARKET SIZE & FORECAST
- 17.2.1 NORTH AMERICA: PRODUCT
- 17.2.2 NORTH AMERICA: TECHNOLOGY
- 17.2.3 NORTH AMERICA: END USER
- 17.3 KEY COUNTRIES
- 17.3.1 US: MARKET SIZE & FORECAST
- 17.3.2 CANADA: MARKET SIZE & FORECAST

18 APAC

- 18.1 MARKET OVERVIEW
- 18.2 MARKET SIZE & FORECAST
- 18.2.1 APAC: PRODUCT
- 18.2.2 APAC: TECHNOLOGY
- 18.2.3 APAC: END USER
- 18.3 KEY COUNTRIES
- 18.3.1 CHINA: MARKET SIZE & FORECAST
- 18.3.2 JAPAN: MARKET SIZE & FORECAST
- 18.3.3 INDIA: MARKET SIZE & FORECAST
- 18.3.4 AUSTRALIA: MARKET SIZE & FORECAST
- 18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST

19 LATIN AMERICA

- 19.1 MARKET OVERVIEW
- 19.2 MARKET SIZE & FORECAST
- 19.2.1 LATIN AMERICA: PRODUCT
- 19.2.2 LATIN AMERICA: TECHNOLOGY
- 19.2.3 LATIN AMERICA: END USER
- 19.3 KEY COUNTRIES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.3.1 BRAZIL: MARKET SIZE & FORECAST
19.3.2 MEXICO: MARKET SIZE & FORECAST
19.3.3 ARGENTINA: MARKET SIZE & FORECAST

20 MIDDLE EAST & AFRICA

- 20.1 MARKET OVERVIEW
- 20.2 MARKET SIZE & FORECAST
- 20.2.1 MIDDLE EAST & AFRICA: PRODUCT
- 20.2.2 MIDDLE EAST & AFRICA: TECHNOLOGY
- 20.2.3 MIDDLE EAST & AFRICA: END USER
- **20.3 KEY COUNTRIES**
- 20.3.1 TURKEY: MARKET SIZE & FORECAST
- 20.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
- 20.3.3 SOUTH AFRICA: MARKET SIZE & FORECAST
- 21 COMPETITIVE LANDSCAPE
- 21.1 COMPETITION OVERVIEW
- 21.2 MARKET SHARE ANALYSIS
- 21.2.1 AALTO BIO REAGENTS
- 21.2.2 FAPON BIOTECH
- 21.2.3 FUJIREBIO
- 21.2.4 MERCK KGAA
- 21.2.5 F. HOFFMANN-LA ROCHE
- 21.2.6 THERMO FISHER SCIENTIFIC
- 22 KEY COMPANY PROFILES
- 22.1 AALTO BIO REAGENTS
- 22.1.1 BUSINESS OVERVIEW
- 22.1.2 AALTO BIO REAGENTS IN IVD RAW MATERIALS MARKET
- 22.1.3 PRODUCT OFFERINGS
- 22.1.4 KEY STRATEGIES
- 22.1.5 KEY STRENGTHS
- 22.1.6 KEY OPPORTUNITIES
- 22.2 FAPON BIOTECH
- 22.2.1 BUSINESS OVERVIEW
- 22.2.2 FAPON BIOTECH IN IVD RAW MATERIALS MARKET
- 22.2.3 PRODUCT OFFERINGS
- 22.2.4 KEY STRATEGIES
- 22.2.5 KEY STRENGTHS
- 22.2.6 KEY OPPORTUNITIES
- 22.3 FUJIREBIO
- 22.3.1 BUSINESS OVERVIEW
- 22.3.2 FUJIREBIO IN IVD RAW MATERIALS MARKET
- 22.3.3 PRODUCT OFFERINGS
- 22.3.4 KEY STRATEGIES
- 22.3.5 KEY STRENGTHS
- 22.3.6 KEY OPPORTUNITIES

Scotts International. EU Vat number: PL 6772247784

- 22.4 MERCK KGAA
- 22.4.1 BUSINESS OVERVIEW
- 22.4.2 MERCK KGAA IN IVD RAW MATERIALS MARKET
- 22.4.3 PRODUCT OFFERINGS
- 22.4.4 KEY STRATEGIES
- 22.4.5 KEY STRENGTHS
- 22.4.6 KEY OPPORTUNITIES
- 22.5 F. HOFFMANN-LA ROCHE
- 22.5.1 BUSINESS OVERVIEW
- 22.5.2 F. HOFFMANN-LA ROCHE IN IVD RAW MATERIALS MARKET
- 22.5.3 PRODUCT OFFERINGS
- 22.5.4 KEY STRATEGIES
- 22.5.5 KEY STRENGTHS
- 22.5.6 KEY OPPORTUNITIES
- 22.6 THERMO FISHER SCIENTIFIC
- 22.6.1 BUSINESS OVERVIEW
- 22.6.2 THERMO FISHER SCIENTIFIC IN IVD RAW MATERIALS MARKET
- 22.6.3 PRODUCT OFFERINGS
- 22.6.4 KEY STRATEGIES
- 22.6.5 KEY STRENGTHS
- 22.6.6 KEY OPPORTUNITIES
- 23 OTHER PROMINENT VENDORS
- 23.1 ABCLONAL
- 23.1.1 BUSINESS OVERVIEW
- 23.1.2 PRODUCT OFFERINGS
- 23.2 BBI SOLUTIONS
- 23.2.1 BUSINESS OVERVIEW
- 23.2.2 PRODUCT OFFERINGS
- 23.3 BEIJING DIAGREAT BIOTECHNOLOGY
- 23.3.1 BUSINESS OVERVIEW
- 23.3.2 PRODUCT OFFERINGS
- 23.4 BIOFOOTPRINTS HEALTHCARE
- 23.4.1 BUSINESS OVERVIEW
- 23.4.2 PRODUCT OFFERINGS
- 23.5 BIOPORTO
- 23.5.1 BUSINESS OVERVIEW
- 23.5.2 PRODUCT OFFERINGS
- 23.6 CREATIVE DIAGNOSTICS
- 23.6.1 BUSINESS OVERVIEW
- 23.6.2 PRODUCT OFFERINGS
- 23.7 CUSABIO TECHNOLOGY
- 23.7.1 BUSINESS OVERVIEW
- 23.7.2 PRODUCT OFFERINGS
- 23.8 EUPROTEIN
- 23.8.1 BUSINESS OVERVIEW
- 23.8.2 PRODUCT OFFERINGS

Scotts International. EU Vat number: PL 6772247784

- 23.9 EXIMIO BIOTEC
- 23.9.1 BUSINESS OVERVIEW
- 23.9.2 PRODUCT OFFERINGS
- 23.10 GENSCRIPT PROBIO
- 23.10.1 BUSINESS OVERVIEW
- 23.10.2 PRODUCT OFFERINGS
- 23.11 GETEIN BIOTECH
- 23.11.1 BUSINESS OVERVIEW
- 23.11.2 PRODUCT OFFERINGS
- 23.12 GLENTHAM LIFE SCIENCES
- 23.12.1 BUSINESS OVERVIEW
- 23.12.2 PRODUCT OFFERINGS
- **23.13 HYTEST**
- 23.13.1 BUSINESS OVERVIEW
- 23.13.2 PRODUCT OFFERINGS
- 23.14 IMMUNODIAGNOSTICS
- 23.14.1 BUSINESS OVERVIEW
- 23.14.2 PRODUCT OFFERINGS
- 23.15 LGC
- 23.15.1 BUSINESS OVERVIEW
- 23.15.2 PRODUCT OFFERINGS
- 23.16 MEDIX BIOCHEMICA
- 23.16.1 BUSINESS OVERVIEW
- 23.16.2 PRODUCT OFFERINGS
- 23.17 MERIDIAN BIOSCIENCE
- 23.17.1 BUSINESS OVERVIEW
- 23.17.2 PRODUCT OFFERINGS
- 23.18 MORE DIAGNOSTICS
- 23.18.1 BUSINESS OVERVIEW
- 23.18.2 PRODUCT OFFERINGS
- 23.19 MP BIOMEDICALS
- 23.19.1 BUSINESS OVERVIEW
- 23.19.2 PRODUCT OFFERINGS
- 23.20 NANIING OKAY BIOTECHNOLOGY
- 23.20.1 BUSINESS OVERVIEW
- 23.20.2 PRODUCT OFFERINGS
- 23.21 NITTO BOSEKI
- 23.21.1 BUSINESS OVERVIEW
- 23.21.2 PRODUCT OFFERINGS
- 23.22 OYC EUROPE
- 23.22.1 BUSINESS OVERVIEW
- 23.22.2 PRODUCT OFFERINGS
- 23.23 PRAHAS HEALTHCARE
- 23.23.1 BUSINESS OVERVIEW
- 23.23.2 PRODUCT OFFERINGS
- 23.24 PROMEGA
- 23.24.1 BUSINESS OVERVIEW

Scotts International. EU Vat number: PL 6772247784

- 23,24,2 PRODUCT OFFERINGS
- 23.25 REAGENT
- 23.25.1 BUSINESS OVERVIEW
- 23.25.2 PRODUCT OFFERINGS
- 23.26 ROCKLAND IMMUNOCHEMICALS
- 23.26.1 BUSINESS OVERVIEW
- 23.26.2 PRODUCT OFFERINGS
- 23.27 SEKISUI DIAGNOSTICS
- 23.27.1 BUSINESS OVERVIEW
- 23.27.2 PRODUCT OFFERINGS
- 23.28 SERION IMMUNOLOGICS
- 23.28.1 BUSINESS OVERVIEW
- 23.28.2 PRODUCT OFFERINGS
- 23.29 SIGNALWAY ANTIBODY
- 23.29.1 BUSINESS OVERVIEW
- 23.29.2 PRODUCT OFFERINGS
- 23.30 SUZHOU YACOO SCIENCE
- 23.30.1 BUSINESS OVERVIEW
- 23.30.2 PRODUCT OFFERINGS
- 23.31 TRINA BIOREACTIVES
- 23.31.1 BUSINESS OVERVIEW
- 23.31.2 PRODUCT OFFERINGS
- 23.32 WATSON INTERNATIONAL
- 23.32.1 BUSINESS OVERVIEW
- 23.32.2 PRODUCT OFFERINGS
- 23.33 WUHAN HUAMEI BIOTECH
- 23.33.1 BUSINESS OVERVIEW
- 23.33.2 PRODUCT OFFERINGS
- 24 REPORT SUMMARY
- 24.1 KEY TAKEAWAYS
- 24.2 STRATEGIC RECOMMENDATIONS
- 25 OUANTITATIVE SUMMARY
- 25.1 MARKET BY PRODUCT
- 25.1.1 EUROPE: PRODUCT SEGMENTATION
- 25.1.2 NORTH AMERICA: PRODUCT SEGMENTATION
- 25.1.3 APAC: PRODUCT SEGMENTATION
- 25.1.4 LATIN AMERICA: PRODUCT SEGMENTATION
- 25.1.5 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
- 25.2 MARKET BY TECHNOLOGY
- 25.2.1 EUROPE: TECHNOLOGY SEGMENTATION
- 25.2.2 NORTH AMERICA: TECHNOLOGY SEGMENTATION
- 25.2.3 APAC: TECHNOLOGY SEGMENTATION
- 25.2.4 LATIN AMERICA: TECHNOLOGY SEGMENTATION
- 25.2.5 MIDDLE EAST & AFRICA: TECHNOLOGY SEGMENTATION
- 25.3 MARKET BY END USER

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

25.3.1 EUROPE: END USER SEGMENTATION

25.3.2 NORTH AMERICA: END-USER SEGMENTATION

25.3.3 APAC: END-USER SEGMENTATION

25.3.4 LATIN AMERICA: END-USER SEGMENTATION

25.3.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION

25.4 MARKET BY GEOGRAPHY

25.4.1 ANTIBODIES & ANTIGENS: GEOGRAPHY SEGMENTATION

25.4.2 ENZYMES: GEOGRAPHY SEGMENTATION

25.4.3 PROTEINS: GEOGRAPHY SEGMENTATION

25.4.4 BIOLOGICAL BUFFERS: GEOGRAPHY SEGMENTATION

25.4.5 OTHER PRODUCTS: GEOGRAPHY SEGMENTATION

25.4.6 CLINICAL CHEMISTRY: GEOGRAPHY SEGMENTATION

25.4.7 IMMUNOCHEMISTRY: GEOGRAPHY SEGMENTATION

25.4.8 MOLECULAR DIAGNOSTICS: GEOGRAPHY SEGMENTATION

25.4.9 OTHER TECHNOLOGIES: GEOGRAPHY SEGMENTATION

25.4.10 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION

25.4.11 DIAGNOSTIC LABORATORIES: GEOGRAPHY SEGMENTATION

25.4.12 OTHER END USERS: GEOGRAPHY SEGMENTATION

26 APPENDIX

26.1 ABBREVIATIONS



☐ - Print this form

To place an Order with Scotts International:

 $\hfill \Box$ - Complete the relevant blank fields and sign

IVD Raw Materials Market - Global Outlook & Forecast 2022-2027

Market Report | 2022-06-20 | 342 pages | Arizton Advisory & Intelligence

Select license	License			Price
	Single User License			\$3500.00
	Team License			\$3995.00
	Enterprisewide			\$4995.00
				VAT
				Total
Email*		Phone*		
First Name*		Last Name*		
First Name* Job title*		Last Name*		
Job title*		Last Name* EU Vat / Tax ID	/ NIP number*	
Job title* Company Name*			/ NIP number*	
Job title* Company Name* Address*		EU Vat / Tax ID	/ NIP number*	
		EU Vat / Tax ID City*	/ NIP number*	

Scotts International. EU Vat number: PL 6772247784